You are here: Industry Insights > sickle cell disease

News List

Government Of Ghana Partners Novartis To Improve Diagnosis, Treatment Of Sickle Cell Disease firstwordpharma
January 28, 2019
The Government of Ghana, through the Ministry of Health, Ghana Health Service and other allied agencies, signed a Memorandum of Understanding (MoU) with Novartis to create a partnership designed to improve the diagnoses and accelerate treatment for people
New Law Boosts Fight Against Sickle Cell Disease drugs
December 20, 2018
A sickle cell disease prevention and treatment program in the United States has been reauthorized to receive nearly $5 million each year over the next five years......
bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology firstwordpharma
December 05, 2018
SCD is a serious, progressively debilitating and life-threatening genetic disease. SCD results from production of abnormal sickle hemoglobin (HbS), which leads to sickled red blood cells (RBCs) and hemolysis.
FDA lifts clinical hold on gene therapy for sickle cell disease biospectrum
October 12, 2018
CRISPR and Vertex entered into a strategic research collaboration in 2015 aimed at the discovery and development of gene editing treatments using the CRISPR/Cas9 technology to correct defects in specific gene targets known to cause or contribute to partic
NIH to accelerate genetic therapies for sickle cell disease biospectrumasia
September 18, 2018
The initiative and its research partners will establish a national data warehouse of genetic therapies for sickle cell disease.
Novo buys into EpiDestiny’s experimental sickle cell therapy pharmatimes
July 18, 2018
Danish drugmaker Novo Nordisk has bought a global licence for EpiDestiny’s sickle cell disease (SCD) programme, EPI01.
FDA Approves Endari for Sickle Cell Disease americanpharmaceuticalreview
July 11, 2017
Emmaus Life Sciences announced the U.S. Food and Drug Administration (FDA) approved Endari (L-glutamine oral powder) to reduce the severe complications of sickle cell disease (SCD) in adult and pediatric patients age 5 and older.
Karolinska Development company Modus Therapeutics raises SEK 32 million to support development of se firstwordpharma
February 21, 2017
Karolinska Development AB has successfully completed a financing round raising SEK 32 million (USD 3.6 million) from existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest.

Previous page 1 2 Next page